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The kidney is the most important organ for water homeostasis and waste
excretion. It performs several important physiological functions for home-
ostasis: it filters the metabolic waste out of circulation, regulates body fluid
balances, and acts as an immune regulator and modulator of cardiovascu-
lar physiology. The development of in vitro renal disease models with
pluripotent stem cells (both human embryonic stem cells and induced
pluripotent stem cells) and the generation of robust protocols for in vitro
derivation of renal-specific-like cells from patient induced pluripotent stem
cells have just emerged. Here we review major findings in the field of kid-
ney regeneration with a major focus on the development of stepwise proto-
cols for kidney cell production from human pluripotent stem cells and the
latest advances in kidney bioengineering (i.e. decellularized kidney scaffolds
and bioprinting). The possibility of generating renal-like three-dimensional
structures to be recellularized with renal-derived induced pluripotent stem
cells may offer new avenues to develop functional kidney grafts
on-demand.
Introduction
Kidney-related diseases constitute one of the major
health challenges in modern society. Chronic kidney
disease (CKD) is a leading cause of mortality and
morbidity in western countries that is estimated to
affect 11% of the adult population. It can progress
toward end-stage renal disease (ESRD), which is incur-
able, often requiring dialysis or preferably renal trans-
plantation. Of note, dialysis treatments alone account
for 2% of national healthcare budgets, and this
parameter is set to double in the next few years. If this
trend were to continue, national governments would
need to spend between 3% and 5% of their annual
healthcare budgets on renal replacement therapies
without taking into account its wider costs in terms of
additional medical expenses.
Currently in the USA there are 122 403 people wait-
ing for lifesaving organ transplants; of these, 101 189
await kidney transplants [1,2]. The median wait time
for an individual’s first kidney transplant is 3.6 years
and can vary depending on different parameters such
as health status, compatibility and organ availability
[2]. Of note, in 2014, 17 105 kidney transplants took
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place in the USA. Of these, 11 570 came from
deceased donors and 5535 came from living donors
[1,2]. The US Department of Health and Human Ser-
vices Organ Procurement and Transplantation Net-
work estimates that over 3000 new patients are added
to the kidney waiting list each month and that in 2014
4270 patients died whilst waiting for a kidney trans-
plant. Thus, there is a serious need for the develop-
ment of new therapeutic strategies that could
overcome these issues.
Recent progress in stem cell based methodologies
and tissue engineering approaches have led to the defi-
nition of novel regenerative medicine strategies for the
treatment of kidney disease. First, the feasibility to
emulate important kidney developmental cues in the
culture dish has shown that under certain conditions
human pluripotent stem cells (hPSCs) can be differen-
tiated in vitro towards the main renal cell types com-
promised during kidney disease (e.g. podocytes and
tubular cells, among others) [3,4]. Second, emerging
technologies including decellularization/recellulariza-
tion and bioprinting technologies have revolutionized
the field of tissue engineering, opening the possibility
of creating complex 3D organs such as kidneys
(reviewed in [5,6]).
Here we review the current advancements in regen-
erative medicine strategies to restore kidney function
with a main focus on (a) the directed differentiation of
hPSCs towards renal-like cells amenable to being used
for kidney engineering and (b) the use of decellulariza-
tion/recellularization and bioprinting technologies. All
these methodologies are envisioned as promising tissue
engineering strategies for kidney bioengineering and
here we discuss the major challenges for the future
translation of these promising technologies into the
clinics (Fig. 1).
Stem cell therapies for kidney
regeneration: challenges and current
status
Kidney-related diseases constitute a major health issue
worldwide [7–9]. The incidence and poor prognosis of
the kidney and its associated diseases reveal the urgent
need not only for development of therapeutic
approaches but also for expanding our understanding
of kidney development and repair potential, especially
nephrons’ generation, differentiation and self-renewal
capacity. Interestingly, the adult mammalian kidney
has the capacity, upon injury, to repair certain cell
types, including tubular and epithelial cell compart-
ments, but not glomerular structures [10–12]. This
seems to take place by proliferation of resident cells,
in the absence of progenitor populations or newly
formed multilineage structures, a process termed ‘cellu-
lar regeneration’ [13]. So far, cellular regeneration has
been traditionally evaluated by lineage tracing pin-
pointing the cellular origin of these proliferating cells
[12–14], whereas progenitor cell populations can be
identified by the ability of the putative candidate cells
Fig. 1. The use of PSCs (both embryonic
stem cells and induced pluripotent stem
cells) opens the door for the identification
of the proper conditions sustaining adult
kidney cells for cell therapy. Similarly,
kidney bioengineering aims to use kidney
scaffolds as biological matrices for further
recellularization, and lately bioprinting has
emerged as a major strategy to build
organ-like structures in three dimensions.
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to differentiate into multiple lineages [15]. Contrary to
other organisms, such as zebrafish and insects, in
which the formation of new nephrons elicits regenera-
tion of lost nephrons, in mammals the formation of
new nephrons is restricted to embryogenesis and com-
pleted by the time of birth [16].
Pluripotent stem cells (PSCs): a potential source
in regenerative medicine
Early in 1998 it was demonstrated that pluripotent
stem cells (PSCs) could be derived from the inner cell
mass of the embryonic blastocyst, resulting in embry-
onic stem cells (ESCs) [17]. Human ESCs (hESCs) rep-
resented then a new source for the study of tissue
development and disease modeling in vitro. From that
initial moment, intense research has been devoted to
the definition of robust protocols for hESC differentia-
tion aiming to generate functional cells able to restore
the loss of function arising during the development of
degenerative diseases. Nevertheless, the molecular
mechanisms involved in lineage restriction of hESCs to
adopt specialized cell types are still under investiga-
tion. Importantly, the most critical impediments to the
use of hESCs in the clinics are the need for human
embryos, which raises ethical concerns, and tissue
rejection after transplantation.
There are other methods to generate PSCs (hPSCs)
from somatic donor cells; these involve cell reprogram-
ming by various methods, including somatic cell
nuclear transfer into an enucleated egg [18], fusion
with a PSC [19], exposure to small chemical com-
pounds [20] and transduction of reprogramming fac-
tors [21]. In the cases of somatic cell nuclear transfer
and cell fusion mediated reprogramming, somatic cell
nuclei are exposed to totipotent or pluripotent envi-
ronments, respectively [22]. On the other hand, the
transduction of the reprogramming factors POU
domain class 5 transcription factor 1 (POU5F1, also
known as OCT3/4), SRY (sex determining region Y)
box 2 (SOX2), Kr€uppel-like factor 4 (KLF4) and mye-
locytomatosis oncogene (c-MYC) (together referred to
as OSKM, the Yamanaka factors) results in the gener-
ation of autocompatible induced pluripotent stem cells
(iPSCs), which share self-renewal and differentiation
potential capacities when compared to hESCs. Most of
the initial studies on patient-iPSC generation have
relied on the use of integrative systems overexpressing
c-MYC and KLF4, two well-known oncogenes [23,24].
To overcome these issues, different laboratories,
including ours, searched for different cell types that
could be reprogrammed in the absence of the two
oncogenic-related factors, taking advantage of the
intrinsic properties from the donor cells of choice (e.g.
cells expressing relatively high levels of any Yamanaka
factor could be reprogrammed in the absence of that
particular gene, such as neural stem cells in the
absence of SOX2). In this regard, iPSCs were effi-
ciently generated in the absence of KLF4 and/or
cMYC from keratinocytes [24], cord blood stem cells
[25] and even neural stem cells [26]. Although these
discoveries revealed the possibility of reducing the
number of factors for iPSC generation, they were still
relying on the use of integrative systems leading to
undesired effects related to random transgene insertion
(e.g. risk of transgene induction after differentiation,
incomplete reprogramming, among others). Very
rapidly, different laboratories worldwide developed
novel methodologies in order to generate transgene-
free iPSCs [27–32], also incorporated important
changes in culture systems (e.g. matrices/media) in
order to produce feeder-free human iPSCs (hiPSCs)
[33–35], and identified soluble compounds replacing
Yamanaka factors for iPSC generation [20]. Together
with these important challenges in the field of iPSC
derivation, intense research has been published on
patient-specific iPSC generation and subsequent differ-
entiation into relevant tissues compromised during dis-
ease progression, providing a unique scenario for
disease modeling [36–41] and even to screen patient-
specific drugs [42,43].
In the same manner, one area that has drawn great
interest is correction of genetic based diseases in
patient-specific hiPSCs with a prospect of precise med-
icine. PSCs are amenable sources for genome editing
because they can undergo extensive tissue culture
manipulations (e.g. drug selection and clonal expan-
sion) while retaining their pluripotency signature and
genome stability [44]. Different research groups have
demonstrated the generation and correction of patient-
specific hiPSCs [38,39,45–49]. These studies have
demonstrated functional correction of the disease-
associated phenotype upon differentiation of patient-
specific hiPSCs, and even opened the door for the
screening of compounds reverting disease phenotype
[49,50], an approach that seems poised to become
the first application of the potential of hiPSCs in
regenerative medicine and human health [51].
Generation of kidney cells from PSCS: PSC based
methodologies model renal development and
disease
Kidney is composed of thousands of nephrons that
arise during development through reciprocal inductive
interactions between two different cell types: the
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metanephric mesenchyme (MM) and the ureteric bud
(UB) derived cells [16]. The MM differentiates into the
different epithelial cell types within the kidney (from
the glomerulus through the connecting segment), and
the UB generates the calyceal system. In the last few
decades many reports have defined culture conditions
for the isolation and in vitro expansion of these cell
populations with limited success (reviewed in
[13,14,52]). An alternative methodology for the genera-
tion of unlimited quantities of kidney-related cell types
is the differentiation of PSCs. In the last few years
independent research groups, including us, have
described for the first time the possibility of generating
different kidney populations from PSCs. In this
regard, Song and colleagues were the first to report on
the derivation of podocyte progenitors from hiPSCs
that were shown to be functional and efficiently inte-
grated in mouse metanephric tissues. However, the
question of which embryonic progenitor cells during
development are equivalent to Song’s iPSC-immature
podocytes remains to be answered [3].
Later in 2013 Mae and colleagues differentiated, for
the first time, monolayers of hESCs towards intermedi-
ate mesoderm (IM), the embryonic tissue that gives
rise to both MM and UB [53]. For this purpose the
authors generated different reporter hiPSC lines in
which GFP was targeted into Odd-skipped related 1
(OSR-1, a gene transiently expressed in the IM during
embryogenesis). Under specific cell culture conditions
IM-differentiated iPSCs showed signatures of other
kidney mature cell types and limited tubular struc-
tures. Interestingly, the same authors pursued the defi-
nition of a chemically defined medium for the
derivation of IM-differentiated iPSCs and recently
described the identification of two retinoid-like mole-
cules inducing IM derivation from iPSCs. In their par-
ticular setting, the authors demonstrated that the
resulting IM-differentiated iPSCs exhibit the capability
to differentiate into multiple kidney cell types, also
developing 3D renal-tubule-like structures in ex vivo
organ culture settings [54].
Along the same line, our group reported for the first
time the possibility of generating UB progenitors from
IM cells from hESCs and from hiPSCs derived from
patients affected by polycystic kidney disease. This was
accomplished with a two-step protocol inducing first
mesodermal specification by bone morphogenetic pro-
tein 4 (BMP4) and fibroblast growth factor 2 (FGF2),
and second IM and renal-like lineages by the exposure
of differentiated cells to retinoic acid, activin A and
BMP2. After 4 days UB progenitors expressed
HOXB7, RET and GFRA1, rather than markers from
MM. Moreover, when UB-like-hiPSC-derived cells
were co-cultured with dissociated E11-5 mouse meta-
nephric cells, the generated cells only integrated into
cytokeratin 8 positive (+) UB-like structures, suggest-
ing the induction of UB lineage-committed IM cells
ex vivo [55].
On the other hand, the Little group have developed
protocols for the generation of well-characterized kid-
ney progenitors from both hESCs and hiPSCs into IM
through the posterior primitive streak, from which IM
is derived during development. The authors made use
of a reporter hESC line for monitoring the expression
of MIXL1 (a gene transiently expressed in the primi-
tive streak during embryogenesis) by knock-in GFP
into MIXL1 locus. The Little group generated two dif-
ferent protocols, one for the simultaneous generation
of MM and UB derivatives and the other for UB cells
alone from PSCs. Noticeably, this work made use of
re-aggregation assays to define the differentiation
potential of the renal-like generated cells, showing that
the re-aggregated differentiated PSCs alone could
organize and generate nephron-like structures [56].
More recently Lam and colleagues reported a rapid
and efficient differentiation protocol for the produc-
tion of PAX2+LHX1+ IM cells from hPSCs that spon-
taneously form tubular-like structures. Interestingly,
Lam showed that hPSC-derived PAX2+LHX1+ IM
cells efficiently integrated into mouse metanephric cul-
tures and differentiated into multipotent nephron pro-
genitor stem cells (NPCs) of the cap mesenchyme
expressing SIX2, SALL1 and WT1 markers [57]. In
the same manner, Taguchi and colleagues have also
shown that it is possible to derive NPCs that possess
the developmental potential to reconstitute 3D
nephron-like structures containing both glomerulus-
like and renal-tubule-like structures in vitro upon co-
culture with embryonic spinal cords from both mouse
ESCs and hiPSCs [58]. In this particular work Taguchi
and colleagues made use of in vivo lineage mouse mod-
els and examined different stages of NPC development
in OSR-1-GFP reporter mice, and found that the
OSR-1-GFP-Integrina+PDGFRa population exhibits
the highest potential to give rise to in vitro forming
nephrons. In this manner the authors redefined the
spatial and temporal location of metanephric nephron
progenitors in vivo, demonstrating that IM contains at
least two metanephric progenitor subpopulations, ante-
rior and posterior domains, and that posteriorly
located IM gives rise to MM lineages [58]. Interest-
ingly this last work outlined when nascent mesoderm
commits to IM and how it becomes specified to MM
and UB lineages [58].
Interestingly, Imberti and colleagues derived renal
progenitor cells from hiPSCs following a two-step
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protocol by first exposing hiPSCs to retinoic acid,
RhoA and PI3K inhibitors and activin A, inducing
IM generation. Next IM-committed hiPSCs were
treated with FGF2, BMP7 and glial-cell-derived neu-
rotrophic factor (GDNF) for 13 additional days in
order to generate MM-derived hiPSCs. Although
other authors had already demonstrated the possibil-
ity of generating MM-derived hPSCs, in this work
Imberti and colleagues demonstrated for the first
time that hiPSC-derived renal progenitors robustly
engrafted into damaged tubuli restoring renal func-
tion [59].
Recently Morizane and colleagues have shown the
possibility of developing NPCs from hPSCs. The work
of Morizane elegantly shows that it is possible to reca-
pitulate MM kidney in vitro and generate SIX2+-
SALL1+WT1+PAX2+ NPCs with 90% efficiency after
9 days. More importantly, the authors proved that
NPCs form kidney organoids in both 2D and 3D set-
tings after 21–28 days, containing epithelial nephron-
like structures expressing markers of podocytes
(PODXL, NPHS1), proximal tubules (CDH2, LTL),
loops of Henle (CDH1, UMOD) and distal tubules
(CDH1, BRN1) mimicking nephron development.
Importantly, the organoid culture system was used to
study the mechanisms of proximal and/or distal tubu-
lar toxicity by exposing kidney organoids to chemical
agents routinely used in animal models in vivo [60].
Along this same line, Freedman and colleagues have
shown that kidney stem cells derived from hPSC-
derived spheroids can be easily derived into kidney
organoids mirroring tissue-specific epithelial physiol-
ogy. In particular the authors were able to knock
out podocalyxin, PKD1 (polycystin-1) or PKD2
(polycystin-2) genes by clustered regularly interspaced
short palindromic repeat (CRISPR)/CAS9 RNA-
guided nucleases CRISPR/Cas9, proving for the first
time the feasibility of 3D renal-derived structures to
model human kidney disease [61]. Very recently Taka-
sato and colleagues [62] has gone one step further in
the generation of kidney organoids containing individ-
ual nephrons that further segmented into distal and
proximal tubules, early loops of Henle and glomeruli
containing podocytes elaborating foot processes and
undergoing vascularization. Like Freedman et al. [61],
Takasato and colleagues also showed that proximal
tubules accumulated dextran cargo and differentially
apoptose in response to cisplatin [62].
Although all these reports showed the possibility of
generating different kidney populations from hPSCs,
they still differ with regard to the reagents used, con-
centrations and timing (Table 1). Importantly, the dif-
ferent findings on PSC differentiation towards renal
lineages revealed that we are still far from identifying
marker genes or surface proteins defining the different
IM populations identified in mice [58].
Genome editing technologies
Recently, different gene editing platforms to increase
homologous recombination efficiency, namely DNA
nucleases (zinc finger nucleases, TAL effector nucleases
and meganucleases), together with CRISPR/Cas9 have
emerged as potential tools for gene editing in patient
hiPSCs [44]. Overall, DNA nucleases and CRISPR/
Cas9 technologies allow for different genome manipu-
lations in a site-specific manner, such as gene activa-
tion/inactivation, sequence deletion, element
replacement and chromosomal rearrangement [44,63].
In the context of kidney disease modeling CRISPR/
Cas9 technology has been used in 3D renal-derived
structures from hiPSCs in order to knock out PKD1
(polycystin-1) and PKD2 (polycystin-2) genes, leading
to the possibility of modeling polycystic kidney disease
in a 3D setting resembling the kidney epithelial com-
partment [61].
Besides the tremendous impacts of genome editing
platforms on human disease modeling, other aspects
recently explored include the use of such technologies
for the generation of PSC reporter cell lines [64–67].
Recently the Little group has developed a new proto-
col for the generation of self-assembling kidney orga-
noids from hPSCs equivalent to the human fetal
kidney during the first trimester of gestation [62].
These results reveal on one hand that we are still far
from developing mature kidney cells with therapeutic
potential, suggesting that new strategies should be
taken into account when developing mature kidney
cells for clinical purposes (e.g. use of conditioned cul-
ture medium from kidney embryonic cells, use of re-
aggregation co-culture systems with human fetal cells,
among others). On the other hand, the mRNA expres-
sion profile in Little et al.’s work arises from different
cell types self-assembled within the kidney 3D struc-
tures, hampering the analysis of the molecular path-
ways sustaining renal differentiation from the different
individual cell types comprising kidney organoids. In
this regard, genome editing technologies, in particular
the CRISPR/Cas system, may help to generate human
reporter PSC lines for the dissection of the molecular
cues driving renal differentiation and thus properly to
evaluate the matureness of the generated cells com-
pared with their in vivo counterparts from developing
embryos.
So far, kidney PSC reporter cell lines have been gen-
erated by means of bacterial artificial chromosome
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based vectors [53] and lentivirus [56]. These seminal
studies have revealed the suitability of reporter cell
lines for the identification and amplification of the
renal cell types of interest (i.e. IM cells and primitive
streak cells) during the onset of differentiation. Impor-
tantly, the Osafune group has gone one step further in
the use of the OSR-1-GFP reporter cell line and identi-
fied two retinoic acid receptor agonists, namely
AM580 and TTNPB, that together with CHIR99021
induced the differentiation of IM cells by activating
the expression of BMP4 [54]. Interestingly the new dif-
ferentiation method using small compounds provided
a less expensive and more consistent method of gener-
ating IM cells than the growth factor method
described previously by the same group [53]. Since the
identification and amplification of tissue-specific renal
stem/progenitor cells with nephrogenic potential is a
critical step in developing cell based therapies for renal
disease, the use of kidney reporter PSCs may result in
the definition of cell culture conditions to be applied
in 3D renal-derived structures from hPSCs.
Novel strategies for kidney
bioengineering
The field of tissue engineering applies the principles of
biology and engineering to the development of func-
tional substitutes for damaged tissue [68]. For decades,
researchers have been struggling to develop a variety
of techniques and methodologies to fabricate bioin-
spired scaffolds using natural or synthetic biomaterials
[69,70]. A consensus in the field is that to be success-
fully used for tissue engineering such scaffolds have to
fulfill several key characteristics in order to encourage
the correct tissue formation and function: (a) be bio-
compatible; (b) possess the appropriate mechanical
strength; (c) show bioactivity in order to modulate the
3D cellular microenvironment; and (d) enable diffusion
of nutrients and clearance of metabolic waste. Signifi-
cant achievements have occurred in the field including
the successful engineering of tissue grafts such as skin
[71], cartilage [72,73], bone [74], bladder [75], blood
vessels [76] and trachea [77]. However, researchers are
nowadays facing new challenges related to the bioengi-
neering of more complex 3D organs like lung, liver,
heart and kidney.
Complex organs require an intact vascular network
that can be further reconnected to the circulatory sys-
tem upon transplantation into the recipient in order to
ensure adequate nutrient and oxygen supply to the
whole organ. Moreover, such organs usually possess
highly organized organ-specific multicellular structures
responsible for performing essential functions. TheT
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kidney represents one of the most complex organs in
terms of development, spatial organization and lineage
specification. A human kidney comprises over 30 dif-
ferent cell types and thousands of intricately patterned
and functionally compartmentalized epithelial struc-
tures named nephrons, which are the functional units
of the kidney. Each nephron is differentiated into dif-
ferent regions, mainly the Bowman’s capsule that
encloses the glomerulus, and the renal tubule, each
having different anatomical features and physiological
roles [16]. Such organ complexity cannot be repro-
duced by traditional scaffold based tissue engineering
methodologies.
Recently, the derivation of organ-specific extracellu-
lar matrix (ECM) scaffolds by decellularization/recellu-
larization and the ability to precisely position cells and
materials by 3D bioprinting technologies have been
envisioned as two of the most promising organ bio-
engineering approaches.
Fabrication of organ scaffolds by
decellularization/recellularization technology
Decellularization of whole organs has opened new per-
spectives on tissue engineering [78] and several labora-
tories have reported on the generation of renal
scaffolds from rodent [79–85], pig [86–88], rhesus mon-
key [89] and human kidneys [5,90,91] (Table 2). A
variety of decellularization protocols have been
described (and reviewed elsewhere [92–94]) which gen-
erally involve the antegrade perfusion of detergents,
enzymes or other cell-lysing solutions through the
organ vasculature to remove the cellular components
while preserving the 3D architecture and biochemical
composition of the native ECM.
After decellularization, kidney scaffolds have been
shown to preserve the glomerular and tubular architec-
ture and the vascular network. Interestingly, some
studies have revealed an essential role of the renal
ECM in modulating cell behavior. Nakayama and col-
leagues showed that hESCs seeded onto decellularized
rhesus monkey kidney ECM formed tubules and
expressed a battery of renal-related markers, and that
those findings were not observed when lung ECMs
were used, indicating a certain degree of specific renal
ECM function [95]. Indeed, in a recent publication by
O’Neill and colleagues [96], papillae-derived renal stem
cells were found to be differentially regulated when
cultured in contact with the different regions of the
kidney ECM, suggesting a regional-specific effect of
the kidney ECM on stem cell behavior. Moreover, in a
recent study by Yu and coworkers [97], rat acellular
ECM kidney scaffolds were grafted in partially
nephrectomized rat kidneys showing some regrowth of
the excised area after 4 weeks of transplantation.
Interestingly, microscopic analysis showed the migra-
tion of nestin-positive cells from the injured kidney
into the grafted decellularized scaffold, indicating that
intact kidney acellular scaffolds retained bioactive
cues. However, no significant renal functional recovery
was reported. Overall, these works support the idea
that acellular kidney ECM retains renal-specific bio-
chemical and biophysical cues that are able to modu-
late cell proliferation and differentiation. Although the
underlying mechanisms are yet to be understood, these
findings suggest that organ ECM scaffolds derived by
decellularization would be an ideal scaffolding system
to provide cells with the appropriate organ-specific
microenvironment for the production of functioning
kidneys.
Despite these encouraging data, the number of stud-
ies that have shown successful transplantation of recel-
lularized whole kidneys has been limited [80,83–85,87].
One of the main hurdles is still the need to efficiently
re-endothelialize the vascular network of the engi-
neered kidney before implantation in order to avoid
extensive thrombosis when being reconnected to the
recipient vasculature. Orlando et al. [87] implanted
decellularized porcine renal scaffolds into recipient
pigs, showing sustained blood pressure during intraop-
erative monitoring; however, after an extended time
period of 2 weeks, the authors reported extensive
thrombosis, pointing out the fact that endothelializa-
tion of the scaffold vasculature is a mandatory require-
ment to ensure successful transplantation over
prolonged time periods. Also Peloso et al. [84]
observed the same problem of thrombus formation
upon implantation of decellularized kidney scaffolds in
a rat model. Remarkably, in a study led by Ott [80],
whole rat acellular kidneys were obtained and recellu-
larized with rat neonatal kidney cells and human
umbilical vein endothelial cells, and further implanted
orthotopically leading to some restoration of renal
filtration and reabsorption. In this relevant proof-of-
concept work, no evidence of bleeding or thrombus
formation was found during the implantation process,
highlighting the importance of re-endothelialization of
the acellular scaffold vasculature. All this work proves
that orthotopic transplantation of the renal scaffolds is
nowadays technically feasible, and that proper recellu-
larization of such scaffolding is needed to further
achieve effective transplantation and organ function.
The optimal source of cells to repopulate acellular
kidney scaffolds is another unsolved question. Current
work has tried to recellularize kidney scaffolds with
different cell sources including neonatal kidney cells
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[80], human umbilical vein endothelial cells [80], mouse
ESC [82,85], hiPSC-derived endothelial cells [83],
immortalized human renal cortical tubular epithelial
cells [83], human pancreatic carcinoma cell line [84]
and porcine primary renal cells [98]. With the recent
advancements in iPSC and gene editing technologies as
well as the latest progress in defining protocols for
renal differentiation of PSCs into relevant kidney cell
types, it appears that renal cells derived from PSCs
would be an ideal cell source for whole organ engi-
neering (as discussed in the section Stem cell therapies
for kidney regeneration above). It is believed that
PSC-derived progenitor renal cells rather than more
mature renal cell phenotypes would be more appropri-
ate to produce a bioengineered kidney. Nevertheless,
much work still needs to be done to precisely
characterize and validate those PSC-derived cell popu-
lations in terms of cell identity, differentiation and
final maturation in order to enable the proper repopu-
lation of the different kidney compartments as well as
to perform the desired renal physiological functions.
Current work typically uses renal artery [79–82,99]
or ureter [79,80] as a route of cell delivery into the kid-
ney scaffold. However, the choice of the route for cell
seeding needs to be further studied given that different
biochemical and biophysical cues from different ECM
compartments could affect cell proliferation, differenti-
ation and further maturation, as suggested already by
some investigations [95,96]. Currently, homemade
bioreactors are used to deliver cells into the kidney
scaffold as well as to ensure uniform delivery of nutri-
ents and oxygen to the recellularized kidney scaffolds.
Song et al. [80] designed a bioreactor that allowed per-
fusion through both the renal artery and the ureter
including a port for the withdrawal of air to generate
a negative pressure environment and produce a tran-
srenal pressure gradient which improved cell seeding
through the ureter. However, a major problem is still
the uneven cell distribution normally observed after
cell seeding, with cells failing to reach the glomeruli in
some cases and generally the inefficacy to reach cell
densities comparable with the ones found in the native
kidney. Therefore, further optimization of bioreactor
systems will be essential in order to achieve complete
recellularization and organ maturation prior to
implantation [100].
Overall, the possibility of combining acellular kidney
ECM scaffolds together with hiPSC-derived renal cells
represents an unprecedented technology platform for
kidney engineering [101]. Already a few papers have
shown the possibility of translating the decellulariza-
tion technology to human kidneys [5,90,91] although
none of them studied their recellularization. Future
directions will need to define the optimal recellulariza-
tion conditions (cell density, cell seeding route and
seeding methodology) in order to improve cell density,
distribution and retention into the different compart-
ments of the kidney acellular scaffold. Moreover, the
scaling up of the technology to recellularize human-
sized kidney scaffolds will require improved cell differ-
entiation protocols, efficient cell delivery strategies and
innovative organ bioreactor systems with physiologi-
cally relevant kidney culture conditions (volume,
pressure, flow rate and mechanical stimuli) in order to
produce functioning human kidneys [100,102].
3D bioprinting
3D bioprinting applies recent developments of additive
manufacturing technologies (also known as 3D print-
ing) to accurately deposit living cells or cell aggregates
together with hydrogel based supporting biomaterials
(altogether termed bioink) into precise geometries to
build organ-like or tissue structures in three dimen-
sions [103,104]. In recent years, novel advancements
have been made in the development of different
bioprinting techniques for the generation of 3D live
tissue-like structures (reviewed in [6]) including those
based on cellular inkjet printing, extrusion, soft lithog-
raphy and laser-induced forward transfer. All of them
consist of a computer-aided device that translates in
three dimensions complex geometries aimed to mimic
specific tissue biological features or even whole organs.
Despite the great potential of this technology in the
field of tissue engineering, one of the major hurdles that
first needs to be solved is the lack of adequate biomate-
rials to support successful bioprinting of living struc-
tures. Much research is being done in this regard in
order to develop new classes of bioinks, as extensively
reviewed elsewhere [105–107]. Interestingly, in recent
work by Pati et al. [108] bioinks from decellularized adi-
pose, cartilage and heart tissues were prepared and used
for printing cell-laden constructs with controlled poros-
ity. The authors demonstrated the possibility of generat-
ing tissue analogues in vitro with either adipogenic or
chondrogenic potential when human adipose derived
stem cells and human inferior turbinate tissue derived
mesenchymal stromal cells were printed using adipose
tissue derived and cartilage tissue derived ECM bioinks
respectively. In the context of kidney regeneration, the
successful generation of functional kidney scaffolds by
bioprinting would be limited by the possibility of mim-
icking kidney ECM in terms of composition and spatial
organization as well as of depositing different renal cell
populations in an organized manner. In this regard,
acellular kidney ECM-derived bioink would be an
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attractive option since it may provide kidney-specific
instructional cues to the printed cells.
Although 3D bioprinting technology is still in its
infancy, it has already shown its potential in organ
regeneration. The group of Atala has been able to
design a printable bladder using modified inkjet bio-
printing technology [109], showing that it is possible to
print different cell types in an organized 3D structure.
This seminal work opened new avenues of organ 3D
printing as a whole. Other approaches such as the use
of tissue spheroids as building blocks have demon-
strated great success in fabricating microtissues such as
vascular networks [110,111] that can be further assem-
bled into organized macrotissues.
Although much work still needs to be done before a
complete fully functional kidney could be printed, a
preliminary step would be the creation of small scale
organoids or functional units such as the nephron that
could be useful for a number of applications such as
drug screening and disease modeling. Already some
recent work has been exploring the use of hPSCs for
bioprinting [112,113] in order to study the possible
effects of the bioprinting process parameters on cell
viability and differentiation potential.
In the context of whole organ engineering, several
challenges need to be taken into account for the imple-
mentation of bioprinting techniques [103,104]: (a) the
development of novel bioinks (i.e. tissue-specific bioinks);
(b) the improvement of bioprinting manufacturing
devices with enough spatial resolution to recapitulate the
hierarchical structure of complex organs and mimic
organ cell densities; (c) the need for vascularization; (d)
the development of adapted perfusion bioreactors suit-
able for organ printing and further organ maturation.
Conclusions
The past 3 years have been exciting for the field of
kidney tissue engineering. Recent work indicates the
feasibility not only to generate kidney cells from
patient-specific iPSCs but to understand the
developmental cues guiding their in vitro production.
The variation in the different findings indicates that
the 3D kidney generated structures when combining
renal-differentiated cells from hPSCs have different
degrees of functional potential. Thus, it has already
been suggested that there is a need to develop further
in vivo assays proving the functionality of the gener-
ated iPSC patient-derived renal cells, such as their
transplantation into a nephrectomy based kidney
injury mouse model. Also and in the quest to under-
stand which molecular components are defining renal
identity during human development, the generation of
reporter PSCs for renal markers is essential for a com-
prehensive analysis of kidney development, leading to
the derivation of novel protocols for the formation of
mature and functional renal cells.
Other issues related to kidney engineering rely on
the development of innovative approaches that can
mimic such organ complexity. Recently, two different
strategies have been attracting much attention among
researchers: whole organ engineering by decellulariza-
tion/recellularization and bioprinting of living organ-
like structures, as they could become a novel source
for organ-on-demand supply.
In conclusion, the continuous advances in the field
of regenerative medicine would directly benefit the
generation of novel strategies for kidney bioengineer-
ing: from the manufacturing of biomimetic scaffolds
and 3D living constructs to the production of iPSC
patient-derived renal cells in the clinical setting.
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